19 and older, any sex, with Joint Diseases or Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Daily Number of Minutes in Moderate/Vigorous Physical ActivityPrimary· Baseline, 13 weeks, 26 weeks, 39 weeks
Time spent in Moderate/Vigorous Physical Activity (MVPA) was measured with a SenseWear Mini sensor over a 7-day period. The mean time was calculated in bouted MVPA per day. A bout is defined as \>= 10 consecutive minutes or more at the level of \>= 3 METs (i.e., the lower bound of MVPA), with allowance for interruption of up to two minutes below the threshold.
Baseline (T0)
Group
Value
95% CI
Immediate Group
31.0
± 37.3
Delayed Group
71.3
± 99.8
13 weeks (T1)
Group
Value
95% CI
Immediate Group
37.7
± 30.5
Delayed Group
49.4
± 63.6
26 weeks (T2)
Group
Value
95% CI
Immediate Group
37.0
± 32.3
Delayed Group
74.6
± 102.1
39 weeks (T3)
Group
Value
95% CI
Immediate Group
34.0
± 25.2
Delayed Group
54.8
± 66.2
Daily Number of Sedentary MinutesSecondary· Baseline, 13 weeks, 26 weeks, 39 weeks
Time spent in sedentary behaviour was measured with a SenseWear Mini sensor over a 7-day period. The mean daily time spent in sedentary activity was calculated with an energy expenditure of \<=1.5 METs, occurring in bouts of \>= 20 minutes during waking hours.
The Pain Subscale ranges from 0 - 100, with 0 indicates extreme knee pain and 100 indicates no knee pain.
Baseline (T0)
Group
Value
95% CI
Immediate Group
72.6
± 13.5
Delay Group
65.1
± 13.7
13 weeks (T1)
Group
Value
95% CI
Immediate Group
73.1
± 15.3
Delay Group
65.9
± 15.6
26 weeks (T2)
Group
Value
95% CI
Immediate Group
72.5
± 18.3
Delay Group
74.8
± 15.4
39 weeks (T3)
Group
Value
95% CI
Immediate Group
72.1
± 19.8
Delay Group
72.8
± 13.2
Knee Injury and Osteoarthritis Outcome Score (KOOS) - Sport and RecreationSecondary· Baseline, 13 weeks, 26 weeks, 39 weeks
The Sport and Recreation Subscale ranges from 0 - 100, with 0 indicates extreme difficulties with sport and recreational activities due to knee problems and 100 indicates no difficulties.
Baseline (T0)
Group
Value
95% CI
Immediate Group
47.9
± 23.7
Delay Group
46.8
± 25.4
13 weeks (T1)
Group
Value
95% CI
Immediate Group
47.1
± 22.4
Delay Group
52.5
± 22.7
26 weeks (T2)
Group
Value
95% CI
Immediate Group
50.5
± 30.1
Delay Group
62.5
± 22.5
39 weeks (T3)
Group
Value
95% CI
Immediate Group
51.6
± 30.4
Delay Group
55.8
± 26.3
Knee Injury and Osteoarthritis Outcome Score (KOOS) - Activity of Daily LivingSecondary· Baseline, 13 weeks, 26 weeks, 39 weeks
The Activity of Daily Living Subscale ranges from 0 - 100, with 0 indicates extreme difficulties with activity of daily living and 100 indicates no difficulties.
Baseline (T0)
Group
Value
95% CI
Immediate Group
75.5
± 14.7
Delay Group
72.2
± 15.8
13 weeks (T1)
Group
Value
95% CI
Immediate Group
75.0
± 13.1
Delay Group
70.3
± 16.9
26 weeks (T2)
Group
Value
95% CI
Immediate Group
77.7
± 18.9
Delay Group
80.3
± 13.1
39 weeks (T3)
Group
Value
95% CI
Immediate Group
74.8
± 20.7
Delay Group
80.0
± 14.0
Knee Injury and Osteoarthritis Outcome Score (KOOS) - Quality of LifeSecondary· Baseline, 13 weeks, 26 weeks, 39 weeks
The Quality of Life Subscale ranges from 0 - 100, with 0 indicates extreme problems with the knee and 100 indicates no problems.
Baseline (T0)
Group
Value
95% CI
Immediate Group
44.0
± 16.0
Delay Group
47.5
± 16.0
13 weeks (T1)
Group
Value
95% CI
Immediate Group
48.7
± 17.5
Delay Group
46.9
± 13.6
26 weeks (T2)
Group
Value
95% CI
Immediate Group
49.4
± 15.7
Delay Group
54.7
± 14.7
39 weeks (T3)
Group
Value
95% CI
Immediate Group
49.3
± 19.1
Delay Group
54.4
± 14.6
The Patient Health Questionnaire-9 (PHQ-9)Secondary· Baseline, 13 weeks, 26 weeks, 39 weeks
The PHQ-9 consists of nine questions (rated from 0 to 3) that correspond to nine diagnostic criteria for major depressive disorder. Range 0-27; lower score = less depressive symptoms),
Baseline (T0)
Group
Value
95% CI
Immediate Group
5.2
± 4.6
Delay Group
5.4
± 5.3
13 weeks (T1)
Group
Value
95% CI
Immediate Group
4.0
± 3.0
Delay Group
4.7
± 4.9
26 weeks (T2)
Group
Value
95% CI
Immediate Group
3.6
± 3.3
Delay Group
4.5
± 5.2
39 weeks (T3)
Group
Value
95% CI
Immediate Group
4.2
± 4.1
Delay Group
4.5
± 5.3
Partners in Health ScaleSecondary· Baseline, Months 3, 6, and 9
The Partners in Health Scale ranges from 0 to 96, calculated from responses to 12 items on a 9-point Likert scale. A score of 0 represents poor self-management, and a score of 96 represents greater self-management capabilities.
Baseline (T0)
Group
Value
95% CI
Immediate Group
76.8
± 11.0
Delay Group
78.0
± 12.0
13 weeks (T1)
Group
Value
95% CI
Immediate Group
76.7
± 11.5
Delay Group
81.6
± 9.6
26 weeks (T2)
Group
Value
95% CI
Immediate Group
78.9
± 9.0
Delay Group
82.6
± 9.3
29 weeks (T3)
Group
Value
95% CI
Immediate Group
81.0
± 7.0
Delay Group
82.6
± 10.0
Self-Reported Habit Index (SRHI) - Sitting at Work SubscaleSecondary· Baseline, 13 weeks, 26 weeks, 39 weeks
The SRHI is a 12-item scale, rated on a 7-point Likert scale, that measures characteristics of habitual behavior. In the Habit index, participants rated their strength of habit for three specific activity-related behaviors: sitting during leisure time at home, sitting during usual occupational activities, and walking outside for 10 minutes. A higher score indicates a stronger habit or behavior that is done frequently, automatically, and done without thinking about it. Range 1-7; higher score = stronger habit.
Baseline (T0)
Group
Value
95% CI
Immediate Group
5.0
± 1.4
Delay Group
4.5
± 2.1
13 weeks (T1)
Group
Value
95% CI
Immediate Group
5.2
± 1.6
Delay Group
4.4
± 2.0
26 weeks (T2)
Group
Value
95% CI
Immediate Group
4.7
± 2.1
Delay Group
4.3
± 2.1
39 weeks (T3)
Group
Value
95% CI
Immediate Group
5.0
± 1.9
Delay Group
4.1
± 2.1
Self-Reported Habit Index (SRHI) - Sitting at Leisure SubscaleSecondary· Baseline, 13 weeks, 26 weeks, 39 weeks
The SRHI is a 12-item scale, rated on a 7-point Likert scale, that measures characteristics of habitual behavior. In the Habit index, participants rated their strength of habit for three specific activity-related behaviors: sitting during leisure time at home, sitting during usual occupational activities, and walking outside for 10 minutes. A higher score indicates a stronger habit or behavior that is done frequently, automatically, and done without thinking about it. Range 1-7; higher score = stronger habit.
The SRHI is a 12-item scale, rated on a 7-point Likert scale, that measures characteristics of habitual behavior. In the Habit index, participants rated their strength of habit for three specific activity-related behaviors: sitting during leisure time at home, sitting during usual occupational activities, and walking outside for 10 minutes. A higher score indicates a stronger habit or behavior that is done frequently, automatically, and done without thinking about it. Range 1-7; higher score = stronger habit.
Baseline (T0)
Group
Value
95% CI
Immediate Group
4.3
± 1.8
Delay Group
4.8
± 2.0
13 weeks (T1)
Group
Value
95% CI
Immediate Group
4.4
± 1.6
Delay Group
4.6
± 2.0
26 weeks (T2)
Group
Value
95% CI
Immediate Group
4.6
± 1.8
Delay Group
4.8
± 1.6
39 weeks (T3)
Group
Value
95% CI
Immediate Group
4.7
± 1.8
Delay Group
4.6
± 1.8
Adverse events — posted to ClinicalTrials.gov
Time frame: 39 weeks.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Physical activity is an essential first-line treatment for patients with knee osteoarthritis (OA). However, only 13% of patients meet the activity recommendation of 150 minutes or more per week. The primary goal of this randomized controlled trial is to assess the efficacy of a Fitbit Flex (a wireless physical activity tracking device) paired with a new application, plus a brief education session and telephone counselling by a physiotherapist (PT), to improve physical activity and reduce sedentary time in patients with knee osteoarthritis.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07391592 — Post Market Clinical Follow-Up Study for EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate
· active not recruiting
NCT06404346 — Comparative Effectiveness of HVT and Bowen Technique in Patients of SI Joint Dysfunction With Upslipped Innominates
· NA
· active not recruiting
NCT05844124 — Impact of Different Exercise Programs on Knee OA
· NA
· active not recruiting
NCT04328181 — Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomo
· NA
· recruiting
Other University of British Columbia trials
Trials by the same sponsor.
NCT07340970 — Sensory Stimuli During Cesarean Delivery
· not yet recruiting
NCT07481201 — Phenylalanine Requirements in the Menstrual Phases
· NA
· not yet recruiting
NCT07492095 — Leucine Requirements in School-Age Children
· NA
· not yet recruiting
NCT07429305 — Combined Tibial Nerve Stimulation and Standing for People With SCI
· NA
· recruiting
NCT07519928 — Exploring the Feasibility and Benefits of Implementing Pelvic Floor Muscle Training During Inpatient Rehabilitation for
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of British Columbia
Last refreshed: 6 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02585323.